ABD-3001
Acute Myeloid Leukemia (AML)
Key Facts
About Advanced Biodesign
Advanced BioDesign is a French biotech founded in 2010 with a mission to treat chemotherapy-resistant cancers by targeting the ALDH1 enzyme family, a key driver of tumor drug resistance and immunomodulation. The company has progressed its lead small-molecule inhibitor, ABD-3001, into clinical trials for AML and has a promising pre-clinical pipeline for solid tumors. Its integrated strategy combines therapeutic inhibitors with a companion diagnostic, ALDESCREEN®, aiming to personalize treatment and improve outcomes for patients with resistant cancers.
View full company profileAbout Advanced Biodesign
Advanced BioDesign is a French biotech founded in 2010 with a mission to treat chemotherapy-resistant cancers by targeting the ALDH1 enzyme family, a key driver of tumor drug resistance and immunomodulation. The company has progressed its lead small-molecule inhibitor, ABD-3001, into clinical trials for AML and has a promising pre-clinical pipeline for solid tumors. Its integrated strategy combines therapeutic inhibitors with a companion diagnostic, ALDESCREEN®, aiming to personalize treatment and improve outcomes for patients with resistant cancers.
View full company profileAbout Advanced Biodesign
Advanced BioDesign is a French biotech founded in 2010 with a mission to treat chemotherapy-resistant cancers by targeting the ALDH1 enzyme family, a key driver of tumor drug resistance and immunomodulation. The company has progressed its lead small-molecule inhibitor, ABD-3001, into clinical trials for AML and has a promising pre-clinical pipeline for solid tumors. Its integrated strategy combines therapeutic inhibitors with a companion diagnostic, ALDESCREEN®, aiming to personalize treatment and improve outcomes for patients with resistant cancers.
View full company profileAbout Advanced Biodesign
Advanced BioDesign is a French biotech founded in 2010 with a mission to treat chemotherapy-resistant cancers by targeting the ALDH1 enzyme family, a key driver of tumor drug resistance and immunomodulation. The company has progressed its lead small-molecule inhibitor, ABD-3001, into clinical trials for AML and has a promising pre-clinical pipeline for solid tumors. Its integrated strategy combines therapeutic inhibitors with a companion diagnostic, ALDESCREEN®, aiming to personalize treatment and improve outcomes for patients with resistant cancers.
View full company profileTherapeutic Areas
Other Acute Myeloid Leukemia (AML) Drugs
| Drug | Company | Phase |
|---|---|---|
| Mipletamig (APVO436) | Aptevo Therapeutics | Phase 1/2 |
| lomonitinib | Lomond Therapeutics | IND-Enabling |
| lonitoclax | Lomond Therapeutics | Phase 1 |
| Menin Inhibitor | Lomond Therapeutics | Discovery |
| AB8939 | AB Science | Phase 1 |
| Small-Molecule Therapeutic | AIkido Labs | Pre-clinical |
| ADI-PEG 20 (pegargiminase) | Polaris Pharma | Phase 1 |
| NC525 | NextCure | Preclinical |
| ACD-101 | Advanced Cellular Dynamics | Phase 1 |
| HC-7366 | HiberCell | Phase 1b |
| Prexigebersen (BP1001) | Bio-Path Holdings | Phase 2 |
| oNKord® (Inaleucel) | Glycostem | Phase 1/2a |